No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.

Background: Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1). Methods: Since race/ethnicity may af...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 68; no. 3; pp. 291 - 301
Main Authors:	Kosoglou, Teddy, Reyderman, Larisa, Kasserra, Claudia, Jennings, Lisa, Young, Sophia, Xuan, Fengjuan, Pei, Jinglan, Maxwell, Stephen, Schiller, James, Meehan, Alan, Cutler, David
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Springer Nature Mar2012
Online Access:	View this record in EBSCOhost